D2-family receptors in schizophrenia: Distribution and implications for treatment

R. A. Lahti, A. C. Lahti, C. A. Tamminga, Ranhosky, H. D. Kleber, R. A. Wise, Sethy

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The distribution of the D2 family of dopamine receptors in human brain argues for an interest in the D3 and D4 receptors in schizophrenia. The D4 receptor is not only the prime target for clozapine but also highly and differentially localized to the neocortex, thalamus, and hippocampus. These are central nervous system areas of direct interest in schizophrenia. The initial therapeutic directions in this area will target receptor antagonists. Moreover, because the D3 receptor may mediate functional actions opposite those mediated by the D2 receptor, its pharmacology in schizophrenia may also be important. The use of selective antagonists to test these concepts is important. Partial agonists at these different receptors should eventually be targeted and tested in schizophrenia since these drugs could have antagonist (antipsychotic) effects without any antagonist side effects. We report early results of tests with (-)-3PPP, which suggest that there is some antipsychotic action, even though tolerance and uneven clinical actions are apparent. These areas are only beginning to be explored in schizophrenia and require much more research to fully exploit. Drugs that are available to the clinician that act selectively at the D2-, D3-, and D4-receptor sites will be essential in this work.

Original languageEnglish (US)
JournalClinical Neuropharmacology
Volume18
Issue numberSUPPL. 1
StatePublished - 1995

Fingerprint

Schizophrenia
Antipsychotic Agents
Dopamine D2 Receptors
Clozapine
Neocortex
Thalamus
Pharmaceutical Preparations
Hippocampus
Central Nervous System
Pharmacology
Brain
Research
Therapeutics

Keywords

  • Agonists and partial agonists
  • Antipsychotics
  • D- and D-receptor antagonists
  • Neuroleptics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Lahti, R. A., Lahti, A. C., Tamminga, C. A., Ranhosky, Kleber, H. D., Wise, R. A., & Sethy (1995). D2-family receptors in schizophrenia: Distribution and implications for treatment. Clinical Neuropharmacology, 18(SUPPL. 1).

D2-family receptors in schizophrenia : Distribution and implications for treatment. / Lahti, R. A.; Lahti, A. C.; Tamminga, C. A.; Ranhosky; Kleber, H. D.; Wise, R. A.; Sethy.

In: Clinical Neuropharmacology, Vol. 18, No. SUPPL. 1, 1995.

Research output: Contribution to journalArticle

Lahti, RA, Lahti, AC, Tamminga, CA, Ranhosky, Kleber, HD, Wise, RA & Sethy 1995, 'D2-family receptors in schizophrenia: Distribution and implications for treatment', Clinical Neuropharmacology, vol. 18, no. SUPPL. 1.
Lahti, R. A. ; Lahti, A. C. ; Tamminga, C. A. ; Ranhosky ; Kleber, H. D. ; Wise, R. A. ; Sethy. / D2-family receptors in schizophrenia : Distribution and implications for treatment. In: Clinical Neuropharmacology. 1995 ; Vol. 18, No. SUPPL. 1.
@article{6000ed84aea5465d80392a241dc517d5,
title = "D2-family receptors in schizophrenia: Distribution and implications for treatment",
abstract = "The distribution of the D2 family of dopamine receptors in human brain argues for an interest in the D3 and D4 receptors in schizophrenia. The D4 receptor is not only the prime target for clozapine but also highly and differentially localized to the neocortex, thalamus, and hippocampus. These are central nervous system areas of direct interest in schizophrenia. The initial therapeutic directions in this area will target receptor antagonists. Moreover, because the D3 receptor may mediate functional actions opposite those mediated by the D2 receptor, its pharmacology in schizophrenia may also be important. The use of selective antagonists to test these concepts is important. Partial agonists at these different receptors should eventually be targeted and tested in schizophrenia since these drugs could have antagonist (antipsychotic) effects without any antagonist side effects. We report early results of tests with (-)-3PPP, which suggest that there is some antipsychotic action, even though tolerance and uneven clinical actions are apparent. These areas are only beginning to be explored in schizophrenia and require much more research to fully exploit. Drugs that are available to the clinician that act selectively at the D2-, D3-, and D4-receptor sites will be essential in this work.",
keywords = "Agonists and partial agonists, Antipsychotics, D- and D-receptor antagonists, Neuroleptics",
author = "Lahti, {R. A.} and Lahti, {A. C.} and Tamminga, {C. A.} and Ranhosky and Kleber, {H. D.} and Wise, {R. A.} and Sethy",
year = "1995",
language = "English (US)",
volume = "18",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 1",

}

TY - JOUR

T1 - D2-family receptors in schizophrenia

T2 - Distribution and implications for treatment

AU - Lahti, R. A.

AU - Lahti, A. C.

AU - Tamminga, C. A.

AU - Ranhosky,

AU - Kleber, H. D.

AU - Wise, R. A.

AU - Sethy,

PY - 1995

Y1 - 1995

N2 - The distribution of the D2 family of dopamine receptors in human brain argues for an interest in the D3 and D4 receptors in schizophrenia. The D4 receptor is not only the prime target for clozapine but also highly and differentially localized to the neocortex, thalamus, and hippocampus. These are central nervous system areas of direct interest in schizophrenia. The initial therapeutic directions in this area will target receptor antagonists. Moreover, because the D3 receptor may mediate functional actions opposite those mediated by the D2 receptor, its pharmacology in schizophrenia may also be important. The use of selective antagonists to test these concepts is important. Partial agonists at these different receptors should eventually be targeted and tested in schizophrenia since these drugs could have antagonist (antipsychotic) effects without any antagonist side effects. We report early results of tests with (-)-3PPP, which suggest that there is some antipsychotic action, even though tolerance and uneven clinical actions are apparent. These areas are only beginning to be explored in schizophrenia and require much more research to fully exploit. Drugs that are available to the clinician that act selectively at the D2-, D3-, and D4-receptor sites will be essential in this work.

AB - The distribution of the D2 family of dopamine receptors in human brain argues for an interest in the D3 and D4 receptors in schizophrenia. The D4 receptor is not only the prime target for clozapine but also highly and differentially localized to the neocortex, thalamus, and hippocampus. These are central nervous system areas of direct interest in schizophrenia. The initial therapeutic directions in this area will target receptor antagonists. Moreover, because the D3 receptor may mediate functional actions opposite those mediated by the D2 receptor, its pharmacology in schizophrenia may also be important. The use of selective antagonists to test these concepts is important. Partial agonists at these different receptors should eventually be targeted and tested in schizophrenia since these drugs could have antagonist (antipsychotic) effects without any antagonist side effects. We report early results of tests with (-)-3PPP, which suggest that there is some antipsychotic action, even though tolerance and uneven clinical actions are apparent. These areas are only beginning to be explored in schizophrenia and require much more research to fully exploit. Drugs that are available to the clinician that act selectively at the D2-, D3-, and D4-receptor sites will be essential in this work.

KW - Agonists and partial agonists

KW - Antipsychotics

KW - D- and D-receptor antagonists

KW - Neuroleptics

UR - http://www.scopus.com/inward/record.url?scp=0029067221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029067221&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029067221

VL - 18

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - SUPPL. 1

ER -